Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Caponnetto V, Russo A, Silvestro M, Tessitore A, De Icco R, Vaghi G, Sances G, Tassorelli C, Baraldi C, Castro FL, Guerzoni S, Prudenzano MP, Fallacara A, Gentile M, Ornello R, Onofri A, Burgalassi A, Chiarugi A, De Cesaris F, Granato A, Casalena A, De Tommaso M, Mampreso E, Merlo P, Coppola G, Battistini S, Rebecchi V, Rainero I, Sepe FN, Dalla Volta G, Sacco S, Geppetti P, Iannone LF; Italian Headache Registry (RICe) Study Group.
Caponnetto V, et al. Among authors: rainero i.
CNS Drugs. 2023 Dec;37(12):1069-1080. doi: 10.1007/s40263-023-01050-3. Epub 2023 Nov 24.
CNS Drugs. 2023.
PMID: 37999868
Free PMC article.